Open Access

Non‑invasive detection of EGFR and TP53 mutations through the combination of plasma, urine and sputum in advanced non‑small cell lung cancer

  • Authors:
    • Zhen Wu
    • Zhen Yang
    • Chun‑Sun Li
    • Wei Zhao
    • Zhi‑Xin Liang
    • Yu Dai
    • Jing Zeng
    • Qiang Zhu
    • Kai‑Ling Miao
    • Dong‑Hua Cui
    • Liang‑An Chen
  • View Affiliations

  • Published online on: August 6, 2019     https://doi.org/10.3892/ol.2019.10726
  • Pages: 3581-3590
  • Copyright: © Wu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

The sensitivity and utility of liquid biopsy in clinical practice requires some improvement. The aim of the present study was to improve the detection of epidermal growth factor (EGFR) and cellular tumor antigen p53 (TP53) mutations in liquid biopsies from patients with advanced non‑small cell lung cancer (NSCLC) by combining plasma, sputum and urine samples under the same sequencing platform. Plasma, sputum and urine samples, and tumor tissues were obtained from 50 patients with NSCLC and were analyzed using next‑generation sequencing. The sensitivity of EGFR‑sensitive mutation detection was 84% in plasma, 63% in sputum, 28% in urine, and 91% when combining the three liquid samples (P<0.001). The sensitivity of TP53 mutation detection increased from 87% in plasma to 94% when the three samples were combined (P<0.001). The sensitivity of EGFR or TP53 mutations detection was higher in patients with multiple metastatic sites compared with patients ≤1 metastatic site. In addition, the progression free survival (PFS) rates obtained following analysis of the three samples independently in patients with EGFR sensitizing mutations were similar, and were 9.0 months in the tissue sample, 7.5 months in plasma, 7.9 months in the sputum and 7.3 months in urine (P=0.721). The PFS of patients with TP53 mutations was shorter compared with patients without TP53 mutations and was as follows: Tissue, 8.2 months compared with 10.2 months (P=0.412); plasma, 8.4 months compared with 10.2 months (P=0.466); sputum, 8.3 months compared with 9.1 months (P=0.904); and when combined, 8.8 months compared with 10.3 months (P=0.599). The combination of plasma, sputum and urine increased the detection of EGFR or TP53 mutation with higher sensitivity, and may improve the predictive value of personalized treatment.

Related Articles

Journal Cover

October 2019
Volume 18 Issue 4

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Wu, Z., Yang, Z., Li, C., Zhao, W., Liang, Z., Dai, Y. ... Chen, L. (2019). Non‑invasive detection of EGFR and TP53 mutations through the combination of plasma, urine and sputum in advanced non‑small cell lung cancer. Oncology Letters, 18, 3581-3590. https://doi.org/10.3892/ol.2019.10726
MLA
Wu, Z., Yang, Z., Li, C., Zhao, W., Liang, Z., Dai, Y., Zeng, J., Zhu, Q., Miao, K., Cui, D., Chen, L."Non‑invasive detection of EGFR and TP53 mutations through the combination of plasma, urine and sputum in advanced non‑small cell lung cancer". Oncology Letters 18.4 (2019): 3581-3590.
Chicago
Wu, Z., Yang, Z., Li, C., Zhao, W., Liang, Z., Dai, Y., Zeng, J., Zhu, Q., Miao, K., Cui, D., Chen, L."Non‑invasive detection of EGFR and TP53 mutations through the combination of plasma, urine and sputum in advanced non‑small cell lung cancer". Oncology Letters 18, no. 4 (2019): 3581-3590. https://doi.org/10.3892/ol.2019.10726